Page 41 - 2019_09-HaematologicaMondo-web

Disease-modifying therapies for SCD
90. Hoppe C, Jacob E, Styles L, Kuypers F, Larkin S, Vichinsky E. Simvastatin reduces vaso-occlusive pain in sickle cell anaemia: a pilot efficacy trial. Br J Haematol. 2017;177(4):620-629.
91. Naik RP, Streiff MB, Lanzkron S. Sickle cell disease and venous thromboembolism: what the anticoagulation expert needs to know. J Thromb Thrombolysis. 2013;35(3): 352-358.
92. Naik RP, Streiff MB, Haywood C, Jr., Nelson JA, Lanzkron S. Venous thromboembolism in adults with sickle cell disease: a serious and under-recognized complication. Am J Med. 2013;126(5):443-449.
93. Shet AS, Wun T. How I diagnose and treat venous thromboembolism in sickle cell dis- ease. Blood. 2018;132(17):1761-1769.
94. Brittain JE, Knoll CM, Ataga KI, Orringer EP, Parise LV. Fibronectin bridges monocytes and reticulocytes via integrin alpha4beta1. Br J Haematol. 2008;141(6):872-881.
95. Dominical VM, Samsel L, Nichols JS, et al. Prominent role of platelets in the formation of circulating neutrophil-red cell heterocellu- lar aggregates in sickle cell anemia. Haematologica. 2014;99(11):e214-217.
96. Wun T, Cordoba M, Rangaswami A, Cheung AW, Paglieroni T. Activated mono- cytes and platelet-monocyte aggregates in patients with sickle cell disease. Clin Lab Haematol. 2002;24(2):81-88.
97. Desai PC, Brittain JE, Jones SK, et al. A pilot study of eptifibatide for treatment of acute pain episodes in sickle cell disease. Thromb Res. 2013;132(3):341-345.
98. Brittain JE, Anea C, Desai P, et al. Effect of eptifibatide on inflammation during acute pain episodes in sickle cell disease. Am J Hematol. 2018;93(4):E99-E101.
99. Wun T, Soulieres D, Frelinger AL, et al. A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease. J Hematol Oncol. 2013;6:17.
100. Heeney MM, Hoppe CC, Abboud MR, et al. A multinational trial of prasugrel for sickle cell vaso-occlusive Events. N Engl J Med. 2016;374(7):625-635.
101.Kanter J, Abboud MR, Kaya B, et al. Ticagrelor does not impact patient-reported pain in young adults with sickle cell disease: a multicentre, randomised phase IIb study. Br J Haematol. 2019;184(2):269-278.
102. Ataga KI, Key NS. Hypercoagulability in sickle cell disease: new approaches to an old problem. Hematology Am Soc Hematol Educ Program. 2007:91-96.
103. Ahmed S, Siddiqui AK, Iqbal U, et al. Effect of low-dose warfarin on D-dimer levels dur- ing sickle cell vaso-occlusive crisis: a brief report. Eur J Haematol. 2004;72(3):213-216.
104. Qari MH, Aljaouni SK, Alardawi MS, et al. Reduction of painful vaso-occlusive crisis of sickle cell anaemia by tinzaparin in a double- blind randomized trial. Thromb Haemost. 2007;98(2):392-396.
105.Shah N, Willen S, Telen MJ, Ortel TL. Prophylactic dose low molecular weight heparin (dalteparin) for treatment of vaso- occlusive pain crisis in patients with sickle cell disease. Blood. 2013;122(21):2241.
106.Hebbel RP. Ischemia-reperfusion injury in sickle cell anemia: relationship to acute chest syndrome, endothelial dysfunction, arterial vasculopathy, and inflammatory pain. Hematol Oncol Clin North Am. 2014;28(2):181-198.
107. Hebbel RP, Osarogiagbon R, Kaul D. The endothelial biology of sickle cell disease: inflammation and a chronic vasculopathy. Microcirculation. 2004;11(2):129-151.
108.Zhang D, Chen G, Manwani D, et al. Neutrophil ageing is regulated by the micro- biome. Nature. 2015;525(7570):528-532.
109.Glassberg J, Minnitti C, Cromwell C, et al. Inhaled steroids reduce pain and sVCAM levels in individuals with sickle cell disease: a triple-blind, randomized trial. Am J Hematol. 2017;92(7):622-631.
110. Langer AL, Leader A, Kim-Schulze S, Ginzburg Y, Merad M, Glassberg J. Inhaled steroids associated with decreased macrophage markers in nonasthmatic indi- viduals with sickle cell disease in a ran- domized trial. Ann Hematol. 2019;98(4): 841-849.
111.Field JJ, Nathan DG, Linden J. Targeting iNKT cells for the treatment of sickle cell dis- ease. Clin Immunol. 2011;140(2):177-183.
112.Field JJ, Lin G, Okam MM, et al. Sickle cell vaso-occlusion causes activation of iNKT cells that is decreased by the adenosine A2A receptor agonist regadenoson. Blood. 2013;121(17):3329-3334.
113.Field JJ, Majerus E, Gordeuk VR, et al. Randomized phase 2 trial of regadenoson for treatment of acute vaso-occlusive crises in sickle cell disease. Blood Adv. 2017;1(20):1645-1649.
114.Field JJ, Majerus E, Ataga KI, et al. NNKTT120, an anti-iNKT cell monoclonal antibody, produces rapid and sustained iNKT cell depletion in adults with sickle cell disease. PloS One. 2017;12(2):e0171067.
115. Owusu-Ansah A, Ihunnah CA, Walker AL, Ofori-Acquah SF. Inflammatory targets of therapy in sickle cell disease. Transl Res. 2016;167(1):281-297.
116. Knight-Perry J, DeBaun MR, Strunk RC, Field JJ. Leukotriene pathway in sickle cell disease: a potential target for directed thera- py. Expert Rev Hematol. 2009;2(1):57-68.
117. Mpollo MS, Quarmyne MO, Rayes O, et al. A phase I trial of zileuton in sickle cell dis- ease. Blood. 2013;122(21):993.
118. Kalish BT, Matte A, Andolfo I, et al. Dietary omega-3 fatty acids protect against vascu- lopathy in a transgenic mouse model of sick- le cell disease. Haematologica. 2015;100(7): 870-880.
119.Lim SH, Morris A, Li K, et al. Intestinal microbiome analysis revealed dysbiosis in sickle cell disease. Am J Hematol. 2018;93 (4):E91-E93.
haematologica | 2019; 104(9)
1719